Suspected Vaccine Induced Prothrombotic Immune Thrombocytopenia (VIPIT)/Vaccine induced immune thrombotic thrombocytopenia VITT):

THANZ Advisory Statement for Haematologists (check for weekly updates):

April 17th, 2021

Purpose of this document:

- Aid clinicians in recognition, diagnosis and management of suspected vaccine associated thrombosis (VIPIT/VITT)

Background

A severe thrombocytopenic thrombotic syndrome has been described in a small proportion of patients exposed to COVID-19 AstraZeneca vaccination. There are reports of possible cases with the J and J COVID-19 vaccine which is not currently being used in Australia or New Zealand.

Antibodies against platelet antigens (PF4) post vaccination have been detected, with some similarity to heparin induced thrombocytopenia (HIT) but with a distinct profile on immuno- and functional testing. This immune thrombosis syndrome is currently being called several names: “VITT”: vaccine induced prothrombotic immune thrombocytopenia; “VATT”: vaccine associated thrombosis and thrombocytopenia; “TTS”: thrombosis with thrombocytopenia syndrome and “VITT” vaccine induced immune thrombotic thrombocytopenia.

Antibodies against PF4 or PF4/polyanion complexes have been detected using ELISA methods, but not other platforms for HIT testing. Platelet activating antibodies on functional testing are considered pathological, and requisite for confirming the diagnosis of VIPIT/VITT. Within Australia, these assays are currently being validated.

Our accepted understanding of this syndrome is rapidly evolving, and we plan to update this advisory statement regularly, accordingly. Information is emerging in peer-reviewed publication and being shared pre-publication.

Patients with any site of new thrombosis who have recently received vaccination against COVID (day 4-20), should be further investigated for VIPIT/VITT as per algorithm on Page 2.

Please ensure you report all suspected adverse effects to the TGA (link provided below).

VIPIT/VITT is a distinct syndrome that is separate to HIT. Standard HIT diagnostic pathways are NOT appropriate for the diagnostic work-up.

Link to request form for specialised investigations: https://www.thanz.org.au/documents/item/579
Patients who have received COVID-19 vaccine

Persistent organ-specific symptoms suggestive of thrombosis
Day 4-28 post vaccination

Platelet count $<150 \times 10^9/L$ AND D-dimer at least 5x Upper Limit of Normal (ULN) +/- low fibrinogen

Proceed with imaging appropriate to site of symptoms

No thrombosis

Consider prophylactic dose anticoagulation with a NON-heparin

ELISA test for anti-PF4 antibodies

Negative

Continue to monitor FBC
Consider repeating ELISA in several days

Positive

Consider therapeutic anticoagulation with a NON-heparin

Functional HIT testing (see text)

Negative

Review requirement for anticoagulant and agent choice in consultation with Haemostasis expert

Positive

Consider therapeutic anticoagulation with a NON-heparin

Thrombosis confirmed
Anticoagulation required
Collect assay samples (see text)

Therapeutic anticoagulation with a NON-heparin
Recommend administration of IVIG 1-2g/kg in 2 doses
NO platelet transfusion

ELISA test for anti-PF4 antibodies AND functional HIT testing

Both assays Negative

Review anticoagulant choice in consultation with Haemostasis expert

Positive

Continue NON-heparin anticoagulant AND discuss with Haemostasis expert

Either assay Positive
When should I suspect VIPIT/VITT?

1. Onset days 4-28 after vaccination
2. Thrombosis: predominant site cerebral venous sinus but splanchnic thrombosis, other VTE and arterial ischaemia have also been reported
3. Thrombocytopenia (*severity and trajectory of thrombocytopenia unclear)
4. High D-Dimer (typically very high)
5. Some patients are refractory to standard anti-coagulation
6. Response to IVIG

*Platelet range 7-149 x 10^9/L in available data

Although most reported cases involve presentation with cerebral venous sinus thrombosis, other sites have also been involved (splanchnic, pulmonary embolism, arterial ischaemia), so any patients presenting with symptoms of thrombosis shortly after vaccination should be considered carefully for VIPIT/VITT, and testing initiated in the appropriate clinical context, even though we currently anticipate most cases of common site venous thrombosis (DVT in the lower leg) will be unrelated to VIPIT/VITT. In the absence of thrombocytopenia, we advise management as per usual VTE pathway in consultation with a sub-specialist thrombosis haematologist (see list of authors at end of statement).

We suspect the timing of greatest risk is between days 4-20 based on case reports to date. Common side effects from immunization can also present with overlapping symptoms within the same timeframe.

Patients presenting with organ specific symptoms of thrombosis (eg. Persisting or severe headaches unresponsive to simple analgesia, abdominal pain or respiratory symptoms) 4-28 days after vaccination should be reviewed carefully for signs of thrombosis or bleeding. Other neurological symptoms of cerebral vein thrombosis can include visual changes, seizures, focal neurological deficits, and general symptoms of encephalopathy. Most cases of VIPIT described to date have been female and aged between 20–55 years, however males have also been affected. In some cases progression of thrombosis whilst on therapeutic heparin anticoagulation is reported.

Not all thrombocytopenia post vaccine is VIPIT/VITT. Immune thrombocytopenia post COVID-19 vaccine is also reported and SHOULD NOT be treated in the same manner. Clinical judgement, as always, should guide management.

A link for a national THANZ database will be available next update
How do I investigate for VIPIT/VITT?

Clinical assessment with appropriate investigations should always be initiated based on the patient context. Do not delay the commencement of life-saving management while awaiting investigations. However, while suspicion of VIPIT/VITT is explored,

1. Do not administer platelet transfusions
2. Do not begin heparin-based anticoagulation (IV unfractionated heparin infusions, LMWH).

Testing for VIPIT/VITT in Australia/New Zealand will occur in at least two stages – A. SCREEN and B. CONFIRM.

A. SCREEN

Blood tests – FBC, D-dimers, fibrinogen levels

1. VIPIT/VITT is suspected if (1) the platelet count is <150x10^9/L AND either (2) D-dimers are elevated (5x upper limit of normal; ULN) OR (3) fibrinogen is reduced. Further serum and plasma samples must be taken (at least 4x blue top citrate tubes and 2 serum clot tubes), specialist haematology consultation is obtained, and locally available radiology must be performed and reported urgently to investigate for relevant organ-specific thrombosis (e.g. CT brain +/- venogram for CSVT, abdominal CT for splanchnic vein thrombosis).
   a. If thrombosis is found, VIPIT/VITT is probable, and treatment must be urgently initiated with IVIG and non-heparin anticoagulation. The Haematologist may consider addition of high dose methylprednisone and/or plasma exchange in the appropriate context (e.g. signs of new/progressive thrombosis).
   b. If no thrombosis is found, VIPIT/VITT is possible, and treatment initiated with non-heparin anticoagulation in prophylactic dose. Haematology may consider the addition of IVIg in the appropriate context (e.g. rapidly falling platelet count with/without bleeding).

2. VIPIT/VITT is much less likely if the platelet count is >150x10^9/L, D-dimers are not elevated AND fibrinogen is normal. If thrombosis is subsequently found, close monitoring of these parameters may remain relevant while treatment is initiated.

3. VIPIT/VITT is less likely if the platelet count is >150x10^9/L, but D-dimers are elevated or fibrinogen is reduced. Re-evaluation and repeat testing may be required in the appropriate context (e.g. ongoing symptoms of severe headaches).

If persistent or escalating symptoms or other concern about thrombosis: rescan and repeat lab tests.

VIPIT/VITT is a distinct syndrome that is separate to HIT. Standard HIT diagnostic pathways are NOT appropriate for the diagnostic work-up.
B. CONFIRM

Patients with suspected VIPIT/VITT either have 1.a) thrombosis (probable) or 1.b) no thrombosis (possible) and should be further investigated as follows:

1. Antigen-based “VITT” immune assay
   - consult your local hemostasis haematologist re: local testing
     a. HIT ELISA appears to detect the antibody
     b. AcuStar, STiC and Particle gel immunoassay (PaGIA) DO NOT detect antibody and are NOT appropriate for use in this setting.

2. Functional antibody testing:
   - Functional testing for platelet activating antibodies associated for VIPIT/VITT are available and being validated. They should be performed in all samples of suspected VIPIT/VITT—consult local haemostasis haematologist.

Please fill out request form, contact local haemostasis expert and send samples to appropriate location as indicated on the request form. https://www.thanz.org.au/documents/item/579

SAMPLES REQUIRED:

For all suspected cases, please collect the following samples at diagnosis prior to treatment:

1. 4 citrate (blue top tubes)
2. 2 serum clot tubes

Diagnostic lab to aliquot double spun plasma and serum into 500uL aliquots, store at -80 degrees or -20 degrees and contact local expert for samples to be directed urgently to sites with testing.
THANZ VIPIT/VITT Advisory Statement: April 17, 2021

How do I treat suspected VIPIT/VITT?

Most cases of suspected VIPIT/VITT will require treatment before results of ELISA testing for PF4 or PF4/polyanion antibodies are available. Specialist consultation with a haematologist will be required.

- **We recommend probable VIPIT/VITT** (suspected WITH thrombosis) to be treated with non-heparin anticoagulation, similar to patients with HIT.
  - IVIg (1-2g/kg over at least 2 divisions) is recommended upfront - particularly for cases that do not respond quickly or are at high risk from deterioration (including presentation platelets < 30 x 10⁹/L, fibrinogen <1.5mg/L).
  - Anticoagulant treatment options are as per local therapeutic practice for HIT: bivalirudin, argatroban, danaparoid, fondaparinux, rivaroxaban, apixaban, dabigatran, and (after initial treatment with another agent) warfarin.
  - Avoid platelet transfusion
  - Anticoagulation duration should probably be time limited (3-6 months), with hospitalisation considered safest until there is a reduction of in vivo platelet activation and thrombin generation (increasing platelets, falling D-dimers, normal fibrinogen).

- **We recommend possible VIPIT/VITT** (suspected WITHOUT thrombosis) be:
  - monitored closely with repeat FBC, D-Dimer, fibrinogen approximately every 3 days
  - Anticoagulation with a non-heparin anticoagulant should be considered – particular with very high D-Dimer and positive immunoassay.
  - We currently recommend consideration of fondaparinux or oral DOAC at prophylactic dosing (alternatives, IV thrombin inhibitors).
  - Avoid platelet transfusion
  - Hospitalisation may be appropriate, until there is a reduction of in vivo platelet activation and thrombin generation (increasing platelets, falling D-dimers, normal fibrinogen).
  - IVIg may be considered if there are any signs to suggest progression of the syndrome despite anticoagulation. Prophylactic administration of IVIg is not yet recommended.
  - Anticoagulation duration should probably be time limited or until HIT ELISA and functional testing is negative.

ITP should be considered – for patients with thrombocytopenia with normal D-Dimer and fibrinogen.

Patients with any site of new thrombosis who have recently received vaccination against COVID (day 4-28), should be further investigated for VIPIT/VITT.

THANZ refers to ATAGI and TGA for vaccination recommendations
THANZ VIPIT/VITT Advisory Statement: April 17, 2021

Glossary

All cases of suspected (probable and possible) VIPIT/VITT (symptoms of thrombosis presenting day 4-28 post vaccination) should be managed along the pathway until excluded by further testing.

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected</td>
<td>VIPIT/VITT is suspected if (1) the platelet count is &lt;150x10^9/L AND either (2) D-dimers are elevated (5x ULN) OR (3) fibrinogen is reduced.</td>
</tr>
<tr>
<td>Probable</td>
<td>VIPIT/VITT is probable if there is evidence of thrombosis in suspected VIPIT/VITT.</td>
</tr>
<tr>
<td>Possible</td>
<td>VIPIT/VITT is possible if there is no evidence of thrombosis in suspected VIPIT/VITT.</td>
</tr>
<tr>
<td>Much less likely</td>
<td>VIPIT/VITT is much less likely if the platelet count is &gt;150x10^9/L, D-dimers are not elevated AND fibrinogen is normal.</td>
</tr>
<tr>
<td>Less likely</td>
<td>VIPIT/VITT is less likely if the platelet count is &gt;150x10^9/L, but D-dimers are elevated or fibrinogen is reduced.</td>
</tr>
<tr>
<td>Strongly supported</td>
<td>VIPIT/VITT is strongly supported by positive “HIT” ELISA testing, or by “HIT” functional testing, in cases of suspected VIPIT/VITT.</td>
</tr>
<tr>
<td>Confirmed</td>
<td>VIPIT/VITT is confirmed by positive “HIT” ELISA, AND positive “HIT” functional testing in cases of suspected VIPIT/VITT.</td>
</tr>
<tr>
<td>Unsupported</td>
<td>VIPIT/VITT is unsupported by negative “HIT” ELISA, and/or negative functional “HIT” testing, in cases of suspected VIPIT/VITT.</td>
</tr>
<tr>
<td>Possible</td>
<td>VIPIT/VITT remains possible in suspected VIPIT/VITT whose “HIT” ELISA is strongly positive, but functional “HIT” testing is negative, or “HIT” ELISA negative but function test positive (Alternative conditions may be required for functional testing).</td>
</tr>
</tbody>
</table>

Dr Vivien Chen, On behalf of the THANZ vaccine thrombocytopenia working group

Authors:

Vivien Chen (Concord Hospital, Sydney)  
Huyen Tran (Alfred Hospital, Melbourne)  
Philip Choi (The Canberra Hospital, ACT)  
Jennifer Curnow (Westmead Hospital, Sydney)  
Sanjeev Chunilal (Monash Medical Centre, Melbourne)  
Christopher Ward (Royal North Shore Hospital, Sydney)  
Freda Passam (Royal Prince Alfred Hospital, Sydney)  
Timothy Brighton (Prince of Wales Hospital, Sydney)  
Beng Chong (St George Hospital, Sydney)  
Robert Bird, (Princess Alexandra Hospital, Brisbane)  
Anoop Enjeti (John Hunter Hospital, Newcastle)  
Leonardo Pasalic (ICPMR, Sydney)  
Emmanuel Favaloro (ICPMR, Sydney)  
Chee Wee Tan (Royal Adelaide Hospital, Adelaide)  
Ross Baker (Perth Blood Institute, Murdoch University, WA)  
Simon McCrae (Launceston Hospital, Tasmania)  
Ibrahim Tohidi-Esfahani (ANZAC Research Institute. Sydney)  
Elizabeth Gardiner (Australian National University, Canberra)  
Joanne Joseph (St Vincent’s hospital, Sydney)  
Danny Hsu (Liverpool hospital, Sydney)  
Laura Young (Auckland City Hospital, NZ)  
Claire McClintock (Auckland City Hospital, NZ)  
Eileen Merriman (Waitemata, NZ)  

Endorsed by THANZ (Thrombosis and Haemostasis Society of Australia and New Zealand)

Publication date: April 17th 2021; Proposed review date: April 22nd, 2021